We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+47.39%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2B
AUM Growth
+$348M
Cap. Flow
+$158M
Cap. Flow %
7.89%
Top 10 Hldgs %
49.36%
Holding
84
New
15
Increased
23
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$49.2M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.6M
3
UTHR icon
United Therapeutics
UTHR
+$39.8M
4
CYTK icon
Cytokinetics
CYTK
+$36.5M
5
ABVX
Abivax
ABVX
+$32.5M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$68.5M
2
RNAM
Avidity Biosciences
RNAM
+$36.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$27.8M
5
ERAS icon
Erasca
ERAS
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.96%
2 Miscellaneous 3.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVBP icon
51
ArriVent BioPharma
AVBP
$1.49B
$8.07M 0.4%
+350,000
New +$7.9M
RLAY icon
52
Relay Therapeutics
RLAY
$4.11B
$7.46M 0.37%
+750,000
New +$6.71M
CRVS icon
53
Corvus Pharmaceuticals
CRVS
$1.19B
$6.58M 0.33%
450,000
-50,000
-10% -$798K
MGTX icon
54
MeiraGTx Holdings
MGTX
$1.33B
$6.06M 0.3%
+700,000
New +$5.32M
JBIO
55
Jade Biosciences
JBIO
$1.33B
$5.62M 0.28%
400,000
+5,000
+1% +$72.4K
VSTM icon
56
Verastem
VSTM
$654M
$5.3M 0.26%
1,000,000
-700,000
-41% -$4.32M
AVTX icon
57
Avalo Therapeutics
AVTX
$1.05B
$4.48M 0.22%
+300,000
New +$4.69M
UNCY icon
58
Unicycive Therapeutics
UNCY
$147M
$3.12M 0.16%
473,563
– –
IBIO icon
59
iBio
IBIO
$67.6M
$2.47M 0.12%
1,300,000
-700,000
-35% -$1.62M
PTN
60
Palatin Technologies
PTN
$18.6M
$2.44M 0.12%
140,000
– –
ACRS icon
61
Aclaris Therapeutics
ACRS
$885M
$1.88M 0.09%
500,000
-100,000
-17% -$337K
PHVS icon
62
Pharvaris
PHVS
$2.48B
$1.84M 0.09%
65,000
-35,000
-35% -$935K
MANE
63
Veradermics Inc
MANE
$4.09B
$1.58M 0.08%
+25,000
New +$1.26M
FTH
64
Faeth Therapeutics
FTH
$874M
$946K 0.05%
+30,000
New +$599K
SEPN
65
Septerna Inc
SEPN
$1.82B
$566K 0.03%
23,548
– –
GUTS icon
66
Fractyl Health
GUTS
$105M
$458K 0.02%
1,000,000
-100,000
-9% -$92.2K
ACLX
67
DELISTED
Arcellx
ACLX
– –
-115,000
Closed -$7.5M
APLS
68
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,000,000
Closed -$25.1M
CDTX
69
DELISTED
Cidara Therapeutics
CDTX
– –
-310,000
Closed -$68.5M
DAWN
70
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-300,000
Closed -$2.8M
DBVT
71
DBV Technologies
DBVT
$851M
– –
-25,000
Closed -$479K
IDYA icon
72
CALL
IDEAYA Biosciences
IDYA
$3.87B
– –
-450,000
Closed -$15.6M
IMTX icon
73
CALL
Immatics
IMTX
$1.44B
– –
-850,000
Closed -$8.93M
JAZZ icon
74
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-200,000
Closed -$34M
KNSA icon
75
Kiniksa Pharmaceuticals
KNSA
$6.09B
– –
-350,000
Closed -$14.4M
1 2
3
4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Logos Global Management held 84 positions worth $2B, up 21% from $1.65B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management deployed $158M of net new capital in Q1 2026, opening 15 new positions and adding to 23 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 85,000 shares worth $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $27.8M trimmed.

  • Logos Global Management's largest Q1 2026 buy was Madrigal Pharmaceuticals: 85,000 shares worth $44.5M.
  • Logos Global Management added most to Centessa Pharmaceuticals in Q1 2026, an estimated $49.2M increase.
  • Logos Global Management's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $27.8M.
  • Logos Global Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $68.5M.
  • Logos Global Management's ten largest holdings make up 49% of its $2B portfolio in Q1 2026.
  • Logos Global Management opened 15 new positions and closed 18 in Q1 2026.
  • Logos Global Management's portfolio value rose 21% quarter-over-quarter to $2B.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.